BGNE BeiGene, Ltd. Stock Quote

BGNE [NASD]

Index	-	P/E	-	EPS (ttm)	-19.07	Insider Own	20.50%	Shs Outstand	91.46M	Perf Week	2.45%
Market Cap	29.08B	Forward P/E	-	EPS next Y	-13.19	Insider Trans	-8.61%	Shs Float	63.36M	Perf Month	3.83%
Income	-1600.70M	PEG	-	EPS next Q	-4.81	Inst Own	60.90%	Short Float	3.88%	Perf Quarter	-16.06%
Sales	308.90M	P/S	94.13	EPS this Y	-13.80%	Inst Trans	-1.01%	Short Ratio	9.45	Perf Half Y	12.14%
Book/sh	43.78	P/B	7.30	EPS next Y	20.70%	ROA	-22.30%	Target Price	358.95	Perf Year	95.79%
Cash/sh	52.89	P/C	6.04	EPS next 5Y	37.00%	ROE	-31.80%	52W Range	155.16 - 388.97	Perf YTD	23.69%
Dividend	-	P/FCF	-	EPS past 5Y	-60.30%	ROI	-37.50%	52W High	-17.83%	Beta	0.88
Dividend %	-	Quick Ratio	4.60	Sales past 5Y	103.70%	Gross Margin	77.10%	52W Low	105.99%	ATR	14.66
Employees	5400	Current Ratio	4.60	Sales Q/Q	75.90%	Oper. Margin	-	RSI (14)	50.45	Volatility	5.10% 4.79%
Optionable	Yes	Debt/Eq	0.15	EPS Q/Q	114.60%	Profit Margin	-	Rel Volume	0.37	Prev Close	308.78
Shortable	Yes	LT Debt/Eq	0.05	Earnings	-	Payout	-	Avg Volume	260.20K	Price	319.61
Recom	2.20	SMA20	0.54%	SMA50	-0.01%	SMA200	9.85%	Volume	97,156	Change	3.51%

Mar-08-21

Initiated

China Renaissance

Buy

Mar-01-21

Downgrade

CLSA

Outperform → Underperform

$330 → $321

Nov-09-20

Downgrade

Ladenburg Thalmann

Buy → Neutral

Nov-06-20

Downgrade

Piper Sandler

Neutral → Underweight

$175 → $185

Nov-06-20

Downgrade

Maxim Group

Buy → Hold

Jul-10-20

Downgrade

CLSA

Buy → Outperform

Mar-13-20

Upgrade

Macquarie

Underperform → Neutral

Feb-18-20

Resumed

Goldman

Buy

Jan-17-20

Upgrade

CLSA

Outperform → Buy

Jan-17-20

Resumed

Morgan Stanley

Overweight

$210

Dec-16-19

Downgrade

Piper Jaffray

Overweight → Neutral

Dec-16-19

Downgrade

Guggenheim

Buy → Neutral

Nov-19-19

Downgrade

UBS

Buy → Neutral

Nov-13-19

Downgrade

CLSA

Buy → Outperform

Nov-04-19

Reiterated

Maxim Group

Buy

$170 → $210

Jun-04-19

Initiated

Bernstein

Outperform

$201

May-10-19

Upgrade

CLSA

Outperform → Buy

Mar-15-19

Initiated

BofA/Merrill

Buy

$200

Jan-04-19

Downgrade

CLSA

Buy → Outperform

Nov-21-18

Initiated

JP Morgan

Overweight

$174

May-12-21 10:00AM	BeiGene Highlights Progress in Hematology at EHA2021 Virtual Congress Business Wire
May-07-21 12:00AM	China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer Business Wire
May-06-21 04:05PM	BeiGene Reports First Quarter 2021 Financial Results Business Wire
Apr-28-21 01:19PM	BeiGene's Stock Is Trading Higher As Brukinsa Drug On Par With JNJ's Imbruvica In Late-Stage Blood Cancer Studies Benzinga +8.69%
07:00AM	BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia Business Wire
Apr-12-21 01:30PM	BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021 Business Wire
08:40AM	BeiGene Reports Phase 1b Data For Sitravatinib And Tislelizumab Combination SmarterAnalyst
Apr-11-21 04:00PM	BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021 Business Wire
Apr-08-21 07:00AM	BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress Business Wire
07:00AM	BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenströms Macroglobulinemia Business Wire
Apr-07-21 07:00PM	BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China Business Wire
Mar-30-21 08:30AM	BeiGene Announces New Chief Financial Officer, Julia Wang Business Wire
Mar-16-21 01:20PM	10 Best Hong Kong Stocks To Buy For 2021 Insider Monkey
Mar-10-21 04:30PM	BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021 Business Wire
07:00AM	BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025 Business Wire
Mar-05-21 08:30AM	BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer Business Wire
Mar-02-21 07:00AM	Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenströms Macroglobulinemia Business Wire
Feb-27-21 01:21AM	BeiGene, Ltd. (NASDAQ:BGNE) Analysts Just Slashed This Year's Revenue Estimates By 33% Simply Wall St.
Feb-26-21 07:00AM	BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan Business Wire
06:41AM	Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy Benzinga
Feb-25-21 04:05PM	BeiGene Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire
Feb-17-21 05:00PM	Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists Business Wire -6.44%
09:33AM	BeiGene's US Application For BRUKINSA In A Type Of Lymphoma, Accepted For Review Benzinga
07:00AM	BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenströms Macroglobulinemia Business Wire
Jan-27-21 05:45PM	BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma Business Wire -10.50%
Jan-26-21 10:01PM	Novartis (NVS) Q4 2020 Earnings Call Transcript Motley Fool
Jan-23-21 01:52AM	Do Institutions Own BeiGene, Ltd. (NASDAQ:BGNE) Shares? Simply Wall St.
Jan-15-21 09:34AM	BeiGene (BGNE) Up on Label Expansion of Tislelizumab in China Zacks
Jan-14-21 04:35PM	Beigene Stock Breaks Out To Record High On Cancer Drug OK In China Investor's Business Daily +8.33%
Jan-13-21 11:00PM	China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer Business Wire +7.34%
Jan-12-21 04:31PM	Beigene Surges Closer To Breakout On $2.2 Billion Deal With Novartis Investor's Business Daily
02:58PM	Novartis (NVS) In-Licenses Anti-PD-1 Antibody from BeiGene Zacks
08:15AM	The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue Benzinga
Jan-11-21 04:30PM	BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab Business Wire
07:00AM	Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strands Next-Generation, Multi-Functional mRNA Technology Business Wire
Jan-07-21 07:00AM	BeiGene to Present at the J.P. Morgan 39th Annual Healthcare Conference Business Wire
Dec-27-20 11:00PM	BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL) Business Wire
Dec-14-20 09:10PM	Is BGNE A Good Stock To Buy Now? Insider Monkey
Dec-11-20 06:17PM	Hudson Executive Reports Cardtronics Stake Barrons.com
Dec-07-20 07:00PM	BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) Business Wire
10:00AM	BeiGene Presents Clinical Data on BRUKINSA® (Zanubrutinib) in B-Cell Malignancies and Waldenströms Macroglobulinemia at the 62nd ASH Annual Meeting Business Wire
Dec-06-20 12:30PM	BeiGene Announces Data on BRUKINSA® (Zanubrutinib) from Phase 2 Trial in Marginal Zone Lymphoma and Phase 3 Trial in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 62nd ASH Annual Meeting Business Wire
Dec-01-20 11:00PM	BeiGene Announces Pricing of Public Offering by Selling Shareholders Business Wire
04:15PM	BeiGene Launches Proposed Public Offering by Selling Shareholders Business Wire
Nov-23-20 07:00AM	BeiGene to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference Business Wire
Nov-20-20 07:37AM	The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga
Nov-19-20 08:00PM	BeiGene Announces the Approval of XGEVA® (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors and in Patients With Multiple Myeloma Business Wire
Nov-17-20 07:00AM	BeiGene Announces that RATIONALE 303 Trial of Tislelizumab in Non-Small Cell Lung Cancer Met the Primary Endpoint of Overall Survival at Interim Analysis Business Wire
Nov-07-20 08:04AM	US$260 - That's What Analysts Think BeiGene, Ltd. (NASDAQ:BGNE) Is Worth After These Results Simply Wall St.
Nov-05-20 04:05PM	BeiGene Reports Third Quarter 2020 Financial Results Business Wire
09:00AM	BeiGene Announces Data on BRUKINSA® (Zanubrutinib) and Tislelizumab to Be Presented at the 62nd ASH Annual Meeting Business Wire
Oct-09-20 07:05AM	How Should Investors React To BeiGene's (NASDAQ:BGNE) CEO Pay? Simply Wall St.
Oct-06-20 07:00AM	BioAtla and BeiGene Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071 Business Wire
Oct-01-20 12:00PM	All You Need to Know About BeiGene, Ltd. (BGNE) Rating Upgrade to Buy Zacks
08:15AM	BeiGene's Shares March Higher, Can It Continue? Zacks
Sep-27-20 06:12AM	3 Top Biotech Stocks to Buy Right Now Motley Fool
Sep-21-20 07:00AM	Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer PR Newswire
Sep-17-20 06:05PM	BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer Business Wire
Sep-10-20 09:00AM	BeiGene to Present at the Morgan Stanley 18th Annual Global Healthcare Conference Business Wire
Sep-09-20 07:00AM	BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenströms Macroglobulinemia Business Wire
Sep-04-20 09:15AM	BeiGene Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs Business Wire
Aug-27-20 08:02AM	The Daily Biotech Pulse: Liver Congress Underway, FDA Approves Companion Diagnostic Test For Clovis Cancer Drug, EUA For Abbott's $5, 15-Minute COVID-19 Test Benzinga
07:00AM	BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals Business Wire
Aug-25-20 07:00AM	BeiGene Appoints Corsee Sanders, Ph.D. to its Board of Directors Business Wire +5.67%
Aug-24-20 08:08AM	Bio-Thera Solutions and BeiGene Announce License, Distribution, and Supply Agreement for Avastin® (Bevacizumab) Biosimilar BAT1706 in China Business Wire
Aug-07-20 12:00PM	What Makes BeiGene, Ltd. (BGNE) a New Buy Stock Zacks
Aug-06-20 04:05PM	BeiGene Reports Second Quarter 2020 Financial Results GlobeNewswire
Aug-05-20 07:00AM	BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress GlobeNewswire
Jul-27-20 09:15AM	Priority Review Granted to BeiGenes New Drug Application of Pamiparib in Ovarian Cancer in China GlobeNewswire
Jul-24-20 06:12PM	13Ds Filings Barrons.com
Jul-20-20 07:53AM	BeiGene, Assembly Bio Ink $540M China HBV Deal; Shares Surge In Pre-Market SmarterAnalyst
06:30AM	Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assemblys Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection GlobeNewswire
Jul-17-20 09:00AM	BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China GlobeNewswire +7.38%
Jul-16-20 10:31AM	Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More Zacks
Jul-15-20 05:00PM	BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering GlobeNewswire
04:19AM	Hillhouse Plans to Invest $1 Billion In Beigenes Share Sale Bloomberg
Jul-14-20 03:43PM	Why BeiGene Stock Jumped Today Motley Fool +11.24%
08:43AM	BeiGene (BGNE) in Focus: Stock Moves 8.7% Higher Zacks
Jul-13-20 10:51AM	Why BeiGene's Stock Is Trading Higher Today Benzinga +8.66%
10:11AM	Amgen (AMGN) Invests Further in China-Based Oncology Partner Zacks
07:53AM	Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money Simply Wall St.
06:40AM	Amgen Pours A Further $421M Into Chinas BeiGene SmarterAnalyst
02:03AM	BeiGene Plans $2B Direct Offering; Analyst Sees Further Upside Ahead SmarterAnalyst
Jul-12-20 09:30PM	Chinese Biotech Beigene to Raise $2.1 Billion in Share Sale Bloomberg
08:00PM	BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering GlobeNewswire
Jul-10-20 11:11AM	Insiders Roundup: Mastercard, Eli Lilly GuruFocus.com
Jul-05-20 04:04PM	Is BeiGene, Ltd. (BGNE) A Good Stock To Buy? Insider Monkey
Jul-02-20 07:00AM	BeiGene to Host Investor Conference Call and Webcast to Discuss the Companys Early Development Pipeline and Research GlobeNewswire
Jul-01-20 06:00PM	BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China GlobeNewswire
08:12AM	The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes Benzinga
07:00AM	BeiGene Announces Appointment of Angus Grant as Chief Business Executive GlobeNewswire
Jun-30-20 07:30PM	BeiGene Begins Commercializing XGEVA® (Denosumab) in China GlobeNewswire
Jun-22-20 09:00AM	BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial GlobeNewswire
Jun-19-20 12:27AM	BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China GlobeNewswire
Jun-18-20 07:30AM	BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenströms Macroglobulinemia GlobeNewswire
Jun-12-20 02:30AM	BeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Association (EHA) Virtual Congress GlobeNewswire
Jun-05-20 07:30AM	BeiGene to Present at the Goldman Sachs 41st Annual Global Healthcare Conference GlobeNewswire
Jun-03-20 07:15AM	BeiGene Announces the Approval of BRUKINSA (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma GlobeNewswire
May-29-20 08:00AM	BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenströms Macroglobulinemia at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program GlobeNewswire
08:00AM	BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program GlobeNewswire

BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wang Xiaodong	Chair, Scientific Advisory Brd	May 10	Option Exercise	0.13	47,503	6,175	5,747,271	May 12 04:32 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	May 10	Sale	300.46	3,394	1,019,752	0	May 12 04:32 PM
Wu Xiaobin	President, COO & GM China	May 03	Sale	343.00	6,715	2,303,245	0	May 05 04:46 PM
Huang Jane	CMO, Hematology	Apr 29	Option Exercise	29.49	1,500	44,235	1,500	May 03 04:35 PM
Huang Jane	CMO, Hematology	Apr 29	Sale	354.92	1,500	532,387	0	May 03 04:35 PM
Huang Jane	CMO, Hematology	Mar 29	Option Exercise	29.49	1,500	44,235	1,500	Mar 31 04:46 PM
Huang Jane	CMO, Hematology	Mar 29	Sale	324.00	1,500	485,993	0	Mar 31 04:46 PM
Huang Jane	CMO, Hematology	Feb 26	Option Exercise	29.49	1,500	44,235	1,500	Mar 02 04:52 PM
Huang Jane	CMO, Hematology	Feb 26	Sale	320.73	1,500	481,099	0	Mar 02 04:52 PM
Huang Jane	CMO, Hematology	Jan 29	Option Exercise	29.49	1,500	44,235	1,500	Feb 02 04:49 PM
Huang Jane	CMO, Hematology	Jan 29	Sale	322.99	1,500	484,492	0	Feb 02 04:49 PM
Liang Howard	CFO & Chief Strategy Officer	Jan 15	Option Exercise	6.50	12,600	81,900	12,600	Jan 19 05:04 PM
Liang Howard	CFO & Chief Strategy Officer	Jan 15	Sale	344.90	12,600	4,345,689	0	Jan 19 05:04 PM
Liang Howard	CFO & Chief Strategy Officer	Jan 14	Option Exercise	6.50	1,400	9,100	1,400	Jan 19 05:04 PM
Liang Howard	CFO & Chief Strategy Officer	Jan 14	Sale	344.47	1,400	482,256	0	Jan 19 05:04 PM
BAKER BROS. ADVISORS LP	Director	Jan 04	Sale	220.50	121,154	26,714,457	968,943	Jan 06 06:32 PM
Huang Jane	CMO, Hematology	Dec 29	Option Exercise	29.49	1,500	44,235	1,500	Dec 30 04:34 PM
Huang Jane	CMO, Hematology	Dec 29	Sale	249.13	1,500	373,690	0	Dec 30 04:34 PM
Liang Howard	CFO & Chief Strategy Officer	Dec 14	Option Exercise	0.87	1,497,200	1,300,000	1,573,715	Dec 16 04:43 PM
Liang Howard	CFO & Chief Strategy Officer	Dec 14	Sale	229.04	91,900	21,048,454	0	Dec 16 04:43 PM
BAKER BROS. ADVISORS LP	Director	Dec 04	Sale	220.50	1,511,546	333,295,893	979,003	Dec 04 05:24 PM
Huang Jane	CMO, Hematology	Nov 30	Option Exercise	29.49	1,500	44,235	1,500	Dec 02 05:01 PM
Huang Jane	CMO, Hematology	Nov 30	Sale	267.82	1,500	401,723	0	Dec 02 05:01 PM
Huang Jane	CMO, Hematology	Oct 29	Option Exercise	29.49	1,500	44,235	1,500	Nov 02 04:44 PM
Huang Jane	CMO, Hematology	Oct 29	Sale	300.06	1,500	450,093	0	Nov 02 04:44 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Oct 16	Sale	320.00	5,000	1,600,000	0	Oct 20 04:44 PM
Liang Howard	CFO & Chief Strategy Officer	Oct 05	Option Exercise	6.50	14,000	91,000	14,000	Oct 07 04:50 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Oct 05	Sale	300.00	5,000	1,500,000	0	Oct 07 04:56 PM
Wu Xiaobin	President & GM China	Oct 05	Sale	300.00	4,000	1,200,000	0	Oct 07 04:52 PM
Liang Howard	CFO & Chief Strategy Officer	Oct 05	Sale	299.60	14,000	4,194,413	0	Oct 07 04:50 PM
Huang Jane	CMO, Hematology	Sep 29	Option Exercise	29.49	1,500	44,235	1,500	Oct 01 04:52 PM
Huang Jane	CMO, Hematology	Sep 29	Sale	280.38	1,500	420,568	0	Oct 01 04:52 PM
OYLER JOHN	Chief Executive Officer	Sep 29	Sale	280.82	23,303	6,544,030	0	Sep 30 04:53 PM
OYLER JOHN	Chief Executive Officer	Sep 28	Sale	280.07	31,000	8,682,063	0	Sep 30 04:53 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Sep 25	Sale	280.42	5,000	1,402,116	0	Sep 29 04:59 PM
Wu Xiaobin	President & GM China	Sep 25	Sale	280.35	4,000	1,121,406	0	Sep 29 04:57 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Sep 17	Sale	260.27	5,000	1,301,356	0	Sep 21 04:53 PM
Wu Xiaobin	President & GM China	Sep 17	Sale	260.33	4,000	1,041,327	0	Sep 21 04:50 PM
OYLER JOHN	Chief Executive Officer	Sep 16	Sale	254.77	27,275	6,948,807	0	Sep 16 05:12 PM
OYLER JOHN	Chief Executive Officer	Sep 15	Sale	254.26	34,214	8,699,381	0	Sep 16 05:12 PM
Liang Howard	CFO & Chief Strategy Officer	Sep 14	Option Exercise	6.50	14,000	91,000	14,000	Sep 16 05:10 PM
OYLER JOHN	Chief Executive Officer	Sep 14	Sale	250.25	19,739	4,939,782	0	Sep 16 05:12 PM
Liang Howard	CFO & Chief Strategy Officer	Sep 14	Sale	250.27	14,000	3,503,764	0	Sep 16 05:10 PM
Huang Jane	CMO, Hematology	Sep 03	Sale	233.07	3,128	729,045	0	Sep 08 04:44 PM
OYLER JOHN	Chief Executive Officer	Sep 02	Sale	229.22	27,807	6,374,024	0	Sep 02 05:44 PM
OYLER JOHN	Chief Executive Officer	Sep 01	Sale	233.79	20,274	4,739,809	0	Sep 02 05:44 PM
OYLER JOHN	Chief Executive Officer	Aug 31	Sale	240.86	12,961	3,121,765	0	Sep 02 05:44 PM
Huang Jane	CMO, Hematology	Aug 28	Option Exercise	29.49	3,000	88,470	3,000	Sep 01 04:41 PM
Huang Jane	CMO, Hematology	Aug 28	Sale	242.21	3,000	726,626	0	Sep 01 04:41 PM
OYLER JOHN	Chief Executive Officer	Aug 21	Sale	240.19	40,788	9,796,775	0	Aug 21 05:21 PM
OYLER JOHN	Chief Executive Officer	Aug 20	Sale	234.62	21,523	5,049,749	0	Aug 21 05:21 PM
OYLER JOHN	Chief Executive Officer	Aug 19	Sale	234.56	29,866	7,005,265	0	Aug 21 05:21 PM
OYLER JOHN	Chief Executive Officer	Aug 14	Sale	211.15	8,705	1,838,034	0	Aug 14 05:30 PM
OYLER JOHN	Chief Executive Officer	Aug 13	Sale	214.48	14,443	3,097,762	0	Aug 14 05:30 PM
Chen Timothy Yung-Cheng	Director	Aug 12	Option Exercise	31.59	2,897	91,516	2,897	Aug 12 05:02 PM
OYLER JOHN	Chief Executive Officer	Aug 12	Sale	212.10	19,820	4,203,766	0	Aug 14 05:30 PM
Chen Timothy Yung-Cheng	Director	Aug 12	Sale	212.00	2,897	614,165	0	Aug 12 05:02 PM
Chen Timothy Yung-Cheng	Director	Aug 11	Option Exercise	31.59	1,903	60,116	1,903	Aug 12 05:02 PM
Chen Timothy Yung-Cheng	Director	Aug 11	Sale	213.04	1,903	405,409	0	Aug 12 05:02 PM
Chen Timothy Yung-Cheng	Director	Aug 10	Option Exercise	31.59	2,200	69,498	2,200	Aug 12 05:02 PM
Chen Timothy Yung-Cheng	Director	Aug 10	Sale	214.04	2,200	470,886	0	Aug 12 05:02 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Aug 10	Sale	211.06	4,000	844,229	0	Aug 12 04:38 PM
OYLER JOHN	Chief Executive Officer	Aug 05	Sale	223.27	17,254	3,852,273	0	Aug 05 05:43 PM
OYLER JOHN	Chief Executive Officer	Aug 04	Sale	220.43	15,383	3,390,951	0	Aug 05 05:30 PM
OYLER JOHN	Chief Executive Officer	Aug 03	Sale	221.78	25,176	5,583,575	0	Aug 05 05:30 PM
Huang Jane	CMO, Hematology	Jul 29	Option Exercise	94.94	3,000	284,835	3,000	Jul 31 04:24 PM
Huang Jane	CMO, Hematology	Jul 29	Sale	209.93	3,000	629,787	0	Jul 31 04:24 PM
OYLER JOHN	Chief Executive Officer	Jul 22	Sale	238.34	27,748	6,613,503	0	Jul 22 06:22 PM
OYLER JOHN	Chief Executive Officer	Jul 21	Sale	251.83	26,413	6,651,695	0	Jul 22 06:14 PM
OYLER JOHN	Chief Executive Officer	Jul 20	Sale	251.85	28,762	7,243,784	0	Jul 22 06:14 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jul 20	Sale	251.31	12,000	3,015,740	0	Jul 22 04:47 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jul 20	Sale	251.98	5,000	1,259,896	0	Jul 22 04:47 PM
Wu Xiaobin	President & GM China	Jul 20	Sale	250.16	2,600	650,407	0	Jul 21 04:50 PM
Wu Xiaobin	President & GM China	Jul 17	Sale	245.74	700	172,015	0	Jul 21 04:50 PM
Wu Xiaobin	President & GM China	Jul 15	Sale	241.11	2,700	650,998	0	Jul 15 05:14 PM
Wu Xiaobin	President & GM China	Jul 13	Sale	220.00	3,000	660,000	0	Jul 15 05:14 PM
OYLER JOHN	Chief Executive Officer	Jul 08	Sale	201.39	17,529	3,530,206	0	Jul 08 05:20 PM
Huang Jane	CMO, Hematology	Jul 07	Option Exercise	160.40	3,921	628,928	3,921	Jul 09 04:43 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jul 07	Sale	200.00	6,000	1,200,000	0	Jul 09 04:45 PM
Huang Jane	CMO, Hematology	Jul 07	Sale	200.00	3,921	784,200	0	Jul 09 04:43 PM
OYLER JOHN	Chief Executive Officer	Jul 07	Sale	198.86	19,023	3,782,987	0	Jul 08 05:20 PM
OYLER JOHN	Chief Executive Officer	Jul 06	Sale	197.11	17,362	3,422,262	0	Jul 08 05:20 PM
OYLER JOHN	Chief Executive Officer	Jul 01	Sale	191.57	3,816	731,016	0	Jul 01 04:43 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jul 01	Sale	190.75	4,847	924,572	0	Jul 06 04:52 PM
Huang Jane	CMO, Hematology	Jun 29	Option Exercise	29.49	1,500	44,235	1,500	Jun 30 04:14 PM
OYLER JOHN	Chief Executive Officer	Jun 29	Sale	192.60	1,435	276,374	0	Jul 01 04:43 PM
Liang Howard	CFO & Chief Strategy Officer	Jun 29	Sale	191.23	300	57,368	0	Jul 01 04:38 PM
Huang Jane	CMO, Hematology	Jun 29	Sale	190.83	1,935	369,250	0	Jun 30 04:14 PM
Huang Jane	CMO, Hematology	Jun 26	Option Exercise	160.40	2,079	333,472	2,079	Jun 30 04:14 PM
Huang Jane	CMO, Hematology	Jun 26	Sale	200.29	2,079	416,397	0	Jun 30 04:14 PM
OYLER JOHN	Chief Executive Officer	Jun 24	Sale	187.34	14,381	2,694,156	0	Jun 24 08:23 PM
OYLER JOHN	Chief Executive Officer	Jun 23	Sale	186.88	15,070	2,816,222	14,381	Jun 24 08:23 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jun 23	Sale	186.38	6,000	1,118,298	0	Jun 24 08:12 PM
OYLER JOHN	Chief Executive Officer	Jun 22	Sale	182.43	10,281	1,875,605	29,451	Jun 24 08:23 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jun 22	Sale	181.33	5,000	906,673	0	Jun 24 08:12 PM
OYLER JOHN	Chief Executive Officer	Jun 10	Sale	175.07	900	157,563	0	Jun 12 04:14 PM
Liang Howard	CFO & Chief Strategy Officer	Jun 08	Sale	170.84	453	77,391	0	Jun 10 05:17 PM
Wu Xiaobin	President & GM China	Jun 08	Sale	170.83	2,800	478,317	0	Jun 10 05:15 PM
Huang Jane	CMO, Hematology	Jun 08	Sale	170.84	631	107,800	0	Jun 10 05:13 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jun 08	Sale	170.91	6,000	1,025,455	0	Jun 10 05:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience